142 related articles for article (PubMed ID: 16819869)
21. Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells.
Wilmes A; Rawson P; Peng L; McLauchlan D; Northcote PT; Jordan TW; Miller JH
Invest New Drugs; 2011 Aug; 29(4):544-53. PubMed ID: 20107863
[TBL] [Abstract][Full Text] [Related]
22. Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.
Begaye A; Trostel S; Zhao Z; Taylor RE; Schriemer DC; Sackett DL
Cell Cycle; 2011 Oct; 10(19):3387-96. PubMed ID: 21926482
[TBL] [Abstract][Full Text] [Related]
23. Conformational analysis of cis-3, 5-dioxa-bicyclo[5.4.0]undecane and its 4-substituted derivatives by DNMR, molecular modeling, and GIAO/DFT methods.
Migda W; Stankiewicz A; Szneler E; Ulman L; Rys B
Magn Reson Chem; 2010 Sep; 48(9):712-7. PubMed ID: 20641136
[TBL] [Abstract][Full Text] [Related]
24. Modulation of lateral and longitudinal interdimeric interactions in microtubule models by Laulimalide and Peloruside A association: A molecular modeling approach on the mechanism of microtubule stabilizing agents.
Zúñiga MA; Alderete JB; Jaña GA; Fernandez PA; Ramos MJ; Jiménez VA
Chem Biol Drug Des; 2018 May; 91(5):1042-1055. PubMed ID: 29316292
[TBL] [Abstract][Full Text] [Related]
25. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.
Gaitanos TN; Buey RM; Díaz JF; Northcote PT; Teesdale-Spittle P; Andreu JM; Miller JH
Cancer Res; 2004 Aug; 64(15):5063-7. PubMed ID: 15289305
[TBL] [Abstract][Full Text] [Related]
26. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity.
Hood KA; West LM; Rouwé B; Northcote PT; Berridge MV; Wakefield SJ; Miller JH
Cancer Res; 2002 Jun; 62(12):3356-60. PubMed ID: 12067973
[TBL] [Abstract][Full Text] [Related]
27. Rotational-echo double-resonance NMR distance measurements for the tubulin-bound Paclitaxel conformation.
Paik Y; Yang C; Metaferia B; Tang S; Bane S; Ravindra R; Shanker N; Alcaraz AA; Johnson SA; Schaefer J; O'Connor RD; Cegelski L; Snyder JP; Kingston DG
J Am Chem Soc; 2007 Jan; 129(2):361-70. PubMed ID: 17212416
[TBL] [Abstract][Full Text] [Related]
28. Conformation of microtubule-bound paclitaxel determined by fluorescence spectroscopy and REDOR NMR.
Li Y; Poliks B; Cegelski L; Poliks M; Gryczynski Z; Piszczek G; Jagtap PG; Studelska DR; Kingston DG; Schaefer J; Bane S
Biochemistry; 2000 Jan; 39(2):281-91. PubMed ID: 10630987
[TBL] [Abstract][Full Text] [Related]
29. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.
Wilmes A; Bargh K; Kelly C; Northcote PT; Miller JH
Mol Pharm; 2007; 4(2):269-80. PubMed ID: 17397239
[TBL] [Abstract][Full Text] [Related]
30. Determination of the preferred conformation of the bicyclic Galerucella pheromone using density functional theory optimization and calculations of chemical shifts.
Bosma WB; Bartelt RJ; Momany FA
J Org Chem; 2006 Jun; 71(13):4748-58. PubMed ID: 16776499
[TBL] [Abstract][Full Text] [Related]
31. Characterizing the laulimalide-peloruside binding site using site-directed mutagenesis of TUB2 in S. cerevisiae.
Hanna R; Maass DR; Atkinson PH; Northcote PT; Teesdale-Spittle PH; Bellows DS; Miller JH
Mol Biosyst; 2014 Jan; 10(1):110-6. PubMed ID: 24161989
[TBL] [Abstract][Full Text] [Related]
32. The tubulin-bound conformation of discodermolide derived by NMR studies in solution supports a common pharmacophore model for epothilone and discodermolide.
Sánchez-Pedregal VM; Kubicek K; Meiler J; Lyothier I; Paterson I; Carlomagno T
Angew Chem Int Ed Engl; 2006 Nov; 45(44):7388-94. PubMed ID: 17036370
[No Abstract] [Full Text] [Related]
33. Synthetic, semisynthetic and natural analogues of peloruside A.
Brackovic A; Harvey JE
Chem Commun (Camb); 2015 Mar; 51(23):4750-65. PubMed ID: 25642465
[TBL] [Abstract][Full Text] [Related]
34. Amphidinolide T, novel 19-membered macrolide from marine dinoflagellate Amphidinium sp.
Tsuda M; Endo T; Kobayashi J
J Org Chem; 2000 Mar; 65(5):1349-52. PubMed ID: 10814095
[TBL] [Abstract][Full Text] [Related]
35. Stereoselective synthesis of a monocyclic peloruside a analogue.
Wullschleger CW; Gertsch J; Altmann KH
Org Lett; 2010 Mar; 12(5):1120-3. PubMed ID: 20141163
[TBL] [Abstract][Full Text] [Related]
36. The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C.
Hood KA; Bäckström BT; West LM; Northcote PT; Berridge MV; Miller JH
Anticancer Drug Des; 2001; 16(2-3):155-66. PubMed ID: 11962513
[TBL] [Abstract][Full Text] [Related]
37. Toward the synthesis of peloruside a: fragment synthesis and coupling studies.
Paterson I; Di Francesco ME; Kühn T
Org Lett; 2003 Feb; 5(4):599-602. PubMed ID: 12583779
[TBL] [Abstract][Full Text] [Related]
38. Strategies for the synthesis of the novel antitumor agent peloruside A.
Williams DR; Nag PP; Zorn N
Curr Opin Drug Discov Devel; 2008 Mar; 11(2):251-71. PubMed ID: 18283613
[TBL] [Abstract][Full Text] [Related]
39. Solution structure of a common substrate mimetic of cyclooxygenase-downstream synthases bound to an engineered thromboxane A2 synthase using a high-resolution NMR technique.
Ruan KH; Wu J; Wang LH
Arch Biochem Biophys; 2005 Dec; 444(2):165-73. PubMed ID: 16297851
[TBL] [Abstract][Full Text] [Related]
40. Stereoselective synthesis of the C(1)-C(11) fragment of peloruside A.
Owen RM; Roush WR
Org Lett; 2005 Sep; 7(18):3941-4. PubMed ID: 16119937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
